Wisp and Vesalius Longevity Labs Partner to Launch Peptide Therapeutics Designed to Address Women’s Health Needs

Audio By Carbonatix

NEW YORK--(BUSINESS WIRE)--Oct 9, 2025--

Wisp, the largest pure play women's telehealth company in the U.S., today announced a strategic partnership with Vesalius Longevity Labs, the market’s first soon-to-be publicly-traded company dedicated exclusively to longevity science. The company behind Peptual, a premium line of peptides and bioregulators, Vesalius will work with Wisp to develop an exclusive range of peptide therapies designed to advance women’s quality of life and promote longevity.

The global peptide therapeutics market is valued at $43.1 billion and is projected to reach $106 billion by 2033. While peptides have been used for decades to treat metabolic illnesses, their recent surge in popularity has been largely driven by men seeking optimized health and performance. Now, Vesalius and Wisp are coming together at the forefront of this commanding trend, unlocking solutions designed around women’s unique biology and effectively doubling the market opportunity.

“Women make up half the population, yet they’ve been treated like an afterthought in the longevity space,” shares Monica Cepak, CEO of Wisp. “Our mission is to close that gap by making advanced therapeutics both accessible and affordable for women at every stage of life. By partnering with Vesalius, we’re introducing peptides into women’s healthcare and expanding access to a powerful tool that can transform how women age.”

Drawing on Vesalius’ existing Peptual product line of primarily US-sourced injectables, patches, nasal sprays, oral and topical formulations this partnership will offer a comprehensive product portfolio designed to address women’s life stages, such as fertility and menopause. Beyond product innovation, Wisp and Vesalius will also jointly evaluate emerging longevity AI platforms for potential integration into their services, exploring opportunities for strategic investment in AI tools that enhance personalized care, clinical decision support, and patient engagement.

“Our product innovation team and globally recognized Scientific Advisory Board are committed to working closely with Wisp to accelerate access to safe, effective solutions,” offers Kevin Rabbitt, CEO of Vesalius Longevity Labs. “By combining Vesalius’ expertise in longevity science with Wisp’s leadership in women’s healthcare, we’re ushering in a new era that will meaningfully extend women’s lifespan.”

Set to launch at the top of 2026, this partnership reflects Wisp’s broader strategy to redefine women’s healthcare. Following this week’s entrance into the longevity category with the launch of two science-backed supplements — Wisp Thrive Creatine Tablets and Wisp Revive Collagen Tablets — the company continues to build on its foundation, establishing its long-term presence across key health verticals. Leveraging strategic partnerships with category leaders like Vesalius, Wisp is creating the next generation of women’s healthcare — bringing innovative treatment options to market and ensuring women have access to the same cutting-edge solutions shaping the future of care.

About Wisp:

Wisp is the largest pure play women’s telehealth provider in the U.S., serving more than 1.5 million patients nationwide. Offering discreet, online care and a comprehensive range of first-to-market products, Wisp addresses women’s health needs across every stage of life—from birth control to fertility, menopause, STI testing, and more. Recognized by Fast Company as one of the Most Innovative Companies of 2023 and by Inc. as Best in Business 2024, Wisp is majority-owned by WELL Health Technologies Corp. Visit hellowisp.com or follow @hellowisp on social media.

About Vesalius Labs:

Vesalius Longevity Labs is a next-generation health and wellness company at the forefront of longevity science. Guided by clinical researchers, physicians, and biotech veterans, Vesalius harnesses the power of peptide innovation to deliver advanced products and services grounded in state-of-the-art research. Through a global, end-to-end B2Doctor ecosystem, Vesalius offers a comprehensive portfolio of injectables, patches, nasal sprays, oral, and topical formulations—primarily U.S.-sourced and manufactured in FDA-registered, cGMP-compliant facilities.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251009748644/en/

CONTACT: Media Contact:

Lilly Bromberg

SolComms

[email protected]

KEYWORD: NEW YORK UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH CONSUMER TELEMEDICINE/VIRTUAL MEDICINE WOMEN OTHER HEALTH FITNESS & NUTRITION PHARMACEUTICAL

SOURCE: Wisp

Copyright Business Wire 2025.

PUB: 10/09/2025 09:00 AM/DISC: 10/09/2025 09:02 AM

http://www.businesswire.com/news/home/20251009748644/en